GUIAS HIPERTENSION ARTERIAL.indb - Scc

262
GUÍAS COLOMBIANAS PARA EL DIAGNÓSTICO
Y TRATAMIENTO DE LA HIPERTENSIÓN ARTERIAL
64. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe
chronic heart failure. N Engl J Med 2001; 344:1651-1658.
65. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol study
II (CIBIS II): A randomized trial. Lancet 1999; 353: 9-13.
66. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced
left ventricular ejection fractions and congestive heart failure. N Engl J Med
1991; 325: 293-302.
67. The Acute Infarction Ramipril Efficacy (AIRE) Study investigators. Effect of Ramipril
on mortality and morbidity of survivors of acute myocardial infarction with clinical
evidence of heart failure. Lancet 1993; 342: 821-828.
68. Kober L, Torp-Pedersen C, Carlsen J, et al. A Clinical trial of the angiotensinconverting-enzyme
inhibitor trandolapril in patients with left ventricular dysfunction
after myocardial infarction. N Engl J Med 1995; 333: 1670-1676.
69. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker
valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
70. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity
and mortality in patients with severe heart failure. The randomized aldactone
evaluation study. N Engl J Med 1999; 341: 709-717.
71. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with
chronic heart failure and reduced left ventricular systolic function intolerant to
angiotensin converting enzyme inhibitors: The CHARM-Alternative trial. Lancet
2003; 362: 772-776.
72. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients
with chronic heart failure and reduced left ventricular systolic function taking
angiotensin converting enzyme inhibitors: the CHARM Added trial. Lancet 2003;
362: 767-771.
73. PROGRESS Collaborative Study Group. Randomised trial of a perindopril-based
blood-pressure-lowering regimen among 6105 individuals with previous stroke
or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
74. Wing LMH, Reid CM, Ryan P, et al, for Second Australian National Blood Pressure
Study Group. A comparison of outcomes with angiotensin-converting-enzyme
inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:
583-592.
75. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset
Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA
2003; 289: 2073-2082.
Revista Colombiana de Cardiología
Febrero 2007
76. Klahr S, Levey AS, Beck GJ, et al, for the Modification of Diet in Renal Disease Study
Group. The effects of dietary protein restriction and blood-pressure control on the
progression of chronic renal disease. N Engl J Med 1994; 330: 877-884.
77. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for
the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Circulation 2004; 110: 227-239.
78. Haffner SM; American Diabetes Association. Dyslipidemia management in adults
with diabetes. Diabetes Care 2004; 27 (Suppl 1): S68-S71.
79. Zinman B, Ruderman N, Campaigne BN, Devlin JT, Schneider SH; American
Diabetes Association. Physical activity/exercise and diabetes mellitus. Diabetes
Care 2003; 26 (Suppl 1): S73-S77.
80. Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C. Physical activity/
exercise and type 2 diabetes. Diabetes Care 2004; 27: 2518-2539.
81. American Diabetes Association. Evidence-based nutrition principles and
recommendations for the treatment and prevention of diabetes and related
complications. Diabetes Care 2002; 25: 202-212.
82. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary
heart disease in subjects with type 2 diabetes and in nondiabetic subjects with
and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
83. Mancia G. The association of hypertension and diabetes: prevalence, cardiovascular
risk and protection by blood pressure reduction. Acta Diabetol 2005;
42 (Suppl 1): S17-S25.
84. Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary
care physicians: blood pressure thresholds, drug choices, and the role of guidelines
and evidence-based medicine. Arch Intern Med 2000; 160: 2281-2286.
85. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade
of the renin-angiotensin system reduces the incidence of new-onset diabetes. J
Hypertens 2005; 23: 463-473.
86. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive
drugs. J Hypertens 2006; 24: 3-10.
87. Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI. The impact of
ACE inhibitors or angiotensin II type 1 receptor blockers on the development of
new-onset type 2 diabetes. Diabetes Care 2005; 28: 2261-2266.
88. Bosch J, Yusuf S, Gerstein HC, et al, for the DREAM Trial Investigators. Effect of
ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-1562.